Inactivated Influenza A H1N1pdm (New York/18/09)

Influenza A/H1N1pdm (New York/18/09) is a strain of the 2009 pandemic H1N1 virus (A/H1N1pdm09). It is primarily transmitted through respiratory droplets expelled through coughing, sneezing, or talking. It can also be spread through direct contact with contaminated surfaces, followed by self-inoculation at the mucous membranes. The virus targets the upper and lower respiratory tracts, binding to the abundant α-2,6-linked sialic acid receptors on human respiratory epithelial cells. Once the virus enters the body, its replication triggers a rapid immune response, leading to symptoms such as fever, cough, and sore throat, and in severe cases, pneumonia or acute respiratory distress syndrome (ARDS). The H1N1pdm strain is highly pathogenic due to its ability to evade pre-existing immunity in the population, partly due to antigenic drift in its hemagglutinin (HA) and neuraminidase (NA) proteins.

Influenza A (H1N1pdm) (New York/18/09) has a typical influenza A virus structure, enclosed in a lipid bilayer membrane derived from the host cell. Embedded within the envelope are the major glycoproteins hemagglutinin (HA) and neuraminidase (NA), which facilitate viral entry and egress, respectively. HA mediates receptor binding and membrane fusion, while NA cleaves sialic acid to release progeny viruses. Matrix protein (M1) resides beneath the envelope, maintaining structural integrity, while ion channel protein (M2) assists in viral uncoating. The viral genome consists of eight single-stranded, negative-sense RNA segments encoding 11 key proteins: PB2, PB1, PA (polymerase complex), HA, NA, NP (nucleoprotein), M1, M2, NS1 (interferon antagonist), NEP (nuclear export protein), and PB1-F2 (apoptosis inducer). The New York/18/09 isolate retains genetic characteristics of the 2009 pandemic strain, including a triple reassortant backbone (of avian, human, and porcine origin) and key HA mutations associated with enhanced virulence (e.g., D222G).